3 results
We aim to optimize the treatment of rheumatoid arthritis patients using concentration measurements. By doing this we hope to reduce the overexposure to the drug, save costs and reduce the number of adverse events, especially infections. The goal of…
The sponsor is developing a biological product (DRL_AB) similar to the approved medicine Orencia®. As part of medical-scientific studies to confirm the similarity of the biological products, the Sponsor wants to compare DRL_AB with EU-approved…
The primary objectives of this study are to assess the safety and estimate the radiation dose of the radioligand [18F]FB610, and to assess the optimal kinetic model for quantification of the tracer uptake. Secondary objectives are to determine…